The Backfill i3+3 Design for Dose-Finding Trials in Oncology
Fuente:
arXiv
Guardado en:
| Autores principales: | Liu, Jiaxin, Yuan, Shijie, Bekele, B. Nebiyou, Ji, Yuan |
|---|---|
| Formato: | Preprint |
| Publicado: |
2023
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology
por: Liu, Jiaxin, et al.
Publicado: (2024)
por: Liu, Jiaxin, et al.
Publicado: (2024)
Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
por: Yuan, Shijie, et al.
Publicado: (2023)
por: Yuan, Shijie, et al.
Publicado: (2023)
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
por: Lee, Kyong Ju, et al.
Publicado: (2025)
por: Lee, Kyong Ju, et al.
Publicado: (2025)
BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
por: Chen, Yuxuan, et al.
Publicado: (2026)
por: Chen, Yuxuan, et al.
Publicado: (2026)
SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
por: Yuan, Shijie, et al.
Publicado: (2025)
por: Yuan, Shijie, et al.
Publicado: (2025)
MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials
por: Lyu, Jiaying, et al.
Publicado: (2020)
por: Lyu, Jiaying, et al.
Publicado: (2020)
Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
por: Hall, Andrew, et al.
Publicado: (2025)
por: Hall, Andrew, et al.
Publicado: (2025)
A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
por: Li, Yuhan, et al.
Publicado: (2024)
por: Li, Yuhan, et al.
Publicado: (2024)
Learning from Literature: Integrating LLMs and Bayesian Hierarchical Modeling for Oncology Trial Design
por: Gong, Guannan, et al.
Publicado: (2026)
por: Gong, Guannan, et al.
Publicado: (2026)
Straightforward Phase I Dose-Finding Design for Healthy Volunteers Accounting for Surrogate Activity Biomarkers
por: Boulet, Sandrine, et al.
Publicado: (2024)
por: Boulet, Sandrine, et al.
Publicado: (2024)
Regulatory Expectations for Bayesian Methods in Drug and Biologic Clinical Trials: A Practical Perspective on FDA's 2026 Draft Guidance
por: Ji, Yuan, et al.
Publicado: (2026)
por: Ji, Yuan, et al.
Publicado: (2026)
Adaptive Phase 2/3 Design with Dose Optimization
por: Chen, Cong, et al.
Publicado: (2024)
por: Chen, Cong, et al.
Publicado: (2024)
Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies
por: Yuan, Shijie, et al.
Publicado: (2025)
por: Yuan, Shijie, et al.
Publicado: (2025)
Adjustment for Inconsistency in Adaptive Phase 2/3 Designs with Dose Optimization
por: Chen, Cong, et al.
Publicado: (2025)
por: Chen, Cong, et al.
Publicado: (2025)
Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs
por: Lu, Feinan, et al.
Publicado: (2024)
por: Lu, Feinan, et al.
Publicado: (2024)
Joint TITE-CRM for Dual Agent Dose Finding Studies
por: Barnett, Helen, et al.
Publicado: (2025)
por: Barnett, Helen, et al.
Publicado: (2025)
Robust Power and Sample Size Calculations in Quasi-likelihood Models: Methods and Practice
por: Yuan, Shijie, et al.
Publicado: (2026)
por: Yuan, Shijie, et al.
Publicado: (2026)
Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control
por: Maity, Arnab Kumar, et al.
Publicado: (2024)
por: Maity, Arnab Kumar, et al.
Publicado: (2024)
Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
por: Sunami, Hisato, et al.
Publicado: (2024)
por: Sunami, Hisato, et al.
Publicado: (2024)
CUI-MET: Clinical Utility Index Dose Optimization Approach for Multiple-Dose, Multiple-Outcome Randomized Trial Designs
por: Zhang, Fanni, et al.
Publicado: (2025)
por: Zhang, Fanni, et al.
Publicado: (2025)
On the Calibration of Bayesian Success Criteria and Operating Characteristics for Clinical Trials
por: Yang, Peng, et al.
Publicado: (2026)
por: Yang, Peng, et al.
Publicado: (2026)
Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review
por: She, Jane, et al.
Publicado: (2026)
por: She, Jane, et al.
Publicado: (2026)
Modeling Time-Varying Effects of Mobile Health Interventions Using Longitudinal Functional Data from HeartSteps Micro-Randomized Trial
por: Yu, Jiaxin, et al.
Publicado: (2024)
por: Yu, Jiaxin, et al.
Publicado: (2024)
Generalized Design of Basket Trials with P-value Combination Test
por: Zhou, Heng, et al.
Publicado: (2024)
por: Zhou, Heng, et al.
Publicado: (2024)
Statistical Design and Rationale of the Biomarkers for Evaluating Spine Treatments (BEST) Trial
por: Sperger, John, et al.
Publicado: (2025)
por: Sperger, John, et al.
Publicado: (2025)
Improving Maximum Tolerated Dose Selection in Model-Assisted Designs for Phase I Trials through Bayesian Dose-Response Model
por: Wakayama, Rentaro, et al.
Publicado: (2025)
por: Wakayama, Rentaro, et al.
Publicado: (2025)
A Bayesian Basket Trial Design Using Local Power Prior
por: Zhou, Haiming, et al.
Publicado: (2023)
por: Zhou, Haiming, et al.
Publicado: (2023)
Age-Dependent Heterogeneity in the Association Between Physical Activity and Mental Distress: A Causal Machine Learning Analysis of 3.2 Million U.S. Adults
por: Shan, Yuan
Publicado: (2026)
por: Shan, Yuan
Publicado: (2026)
Bayesian Design and Analysis of Precision Trials with Partial Borrowing
por: Golchi, Shirin, et al.
Publicado: (2026)
por: Golchi, Shirin, et al.
Publicado: (2026)
Two-stage Adaptive Design Cluster Randomised Trials
por: Watson, Samuel I., et al.
Publicado: (2026)
por: Watson, Samuel I., et al.
Publicado: (2026)
Personalized Oncology: Feasibility of Evaluating Treatment Effects for Individual Patients
por: Jang, Lydia, et al.
Publicado: (2025)
por: Jang, Lydia, et al.
Publicado: (2025)
Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
por: Amevor, Robert, et al.
Publicado: (2026)
por: Amevor, Robert, et al.
Publicado: (2026)
Hybrid Non-informative and Informative Prior Model-assisted Designs for Mid-trial Dose Insertion
por: Yamada, Kana, et al.
Publicado: (2026)
por: Yamada, Kana, et al.
Publicado: (2026)
Remote, bivariate expert elicitation to determine the prior probability distribution for sample size calculation in a Bayesian non-inferiority multicenter randomized controlled trial (Croup Dosing Trial)
por: Jiang, Arlene, et al.
Publicado: (2026)
por: Jiang, Arlene, et al.
Publicado: (2026)
On Assessing Overall Survival (OS) in Oncology Studies
por: Hsu, Jason C.
Publicado: (2025)
por: Hsu, Jason C.
Publicado: (2025)
Second-order Asymptotic Analysis of Tail Probabilities of Randomly Weighted Sums: With Applications to a Bidimensional Discrete-time Risk Model
por: Geng, Bingzhen, et al.
Publicado: (2025)
por: Geng, Bingzhen, et al.
Publicado: (2025)
Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective
por: Chen, Jie, et al.
Publicado: (2024)
por: Chen, Jie, et al.
Publicado: (2024)
Dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials
por: Silva, Rebecca B., et al.
Publicado: (2025)
por: Silva, Rebecca B., et al.
Publicado: (2025)
Sample size and power determination for assessing overall SNP effects in joint modeling of longitudinal and time-to-event data
por: Bian, Yuan, et al.
Publicado: (2026)
por: Bian, Yuan, et al.
Publicado: (2026)
Same Prompt, Different Outcomes: Evaluating the Reproducibility of Data Analysis by LLMs
por: Cui, Jiaxin, et al.
Publicado: (2026)
por: Cui, Jiaxin, et al.
Publicado: (2026)
Ejemplares similares
-
The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology
por: Liu, Jiaxin, et al.
Publicado: (2024) -
Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
por: Yuan, Shijie, et al.
Publicado: (2023) -
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
por: Lee, Kyong Ju, et al.
Publicado: (2025) -
BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
por: Chen, Yuxuan, et al.
Publicado: (2026) -
SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
por: Yuan, Shijie, et al.
Publicado: (2025)